title: L-methionine decreases dendritic spine density in mouse frontal cortex.
abstract: Schizophrenia postmortem brain is characterized by gamma aminobutyric acid downregulation and by decreased dendritic spine density in frontal cortex. Protracted L-methionine treatment exacerbates schizophrenia symptoms, and our earlier work (Tremolizzo et al. and Dong et al.) has shown that L-methionine decreases reelin and GAD67 transcription in mice which is prevented by co-administration of valproate. In this study, we observed a decrease in spine density following L-methionine treatment, which was prevented by co-administration of valproate. Together with our earlier findings conducted under the same experimental conditions, we suggest that downregulation of spine density in L-methionine-treated mice may be because of the decreased expression of reelin and that valproate may prevent spine downregulation by inhibiting the methylation induced decrease in reelin.
authors.affiliation: Department of Psychiatry, Psychiatric Institute, College of Medicine, University of Illinois at Chicago, USA. ptueting@psych.uic.edu
authors.forename: Patricia
authors.initials: P
authors.lastname: Tueting
authors.forename: John M
authors.initials: JM
authors.lastname: Davis
authors.forename: Marin
authors.initials: M
authors.lastname: Veldic
authors.forename: Fabio
authors.initials: F
authors.lastname: Pibiri
authors.forename: Bashkim
authors.initials: B
authors.lastname: Kadriu
authors.forename: Alessandro
authors.initials: A
authors.lastname: Guidotti
authors.forename: Erminio
authors.initials: E
authors.lastname: Costa
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use; D015816:Cell Adhesion Molecules, Neuronal / Q000187:drug effects / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D048430:Cell Shape / Q000187:drug effects / Q000502:physiology; D049229:Dendritic Spines / Q000187:drug effects* / Q000473:pathology*; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D004347:Drug Interactions / Q000502:physiology; D016326:Extracellular Matrix Proteins / Q000187:drug effects / Q000378:metabolism; D005625:Frontal Lobe / Q000187:drug effects* / Q000473:pathology* / Q000503:physiopathology; D018682:GABA Agents / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008715:Methionine / Q000378:metabolism / Q000633:toxicity*; D008745:Methylation / Q000187:drug effects; D051379:Mice; D009419:Nerve Tissue Proteins / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D009498:Neurotoxins / Q000378:metabolism / Q000633:toxicity; D000091042:Reelin Protein; D012559:Schizophrenia / Q000139:chemically induced / Q000473:pathology* / Q000503:physiopathology; D012697:Serine Endopeptidases / Q000187:drug effects / Q000378:metabolism; D013569:Synapses / Q000187:drug effects / Q000473:pathology; D014635:Valproic Acid / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D015816:Cell Adhesion Molecules, Neuronal; D016326:Extracellular Matrix Proteins; D018682:GABA Agents; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D009498:Neurotoxins; D000091042:Reelin Protein; D014635:Valproic Acid; D008715:Methionine; C000717128:Reln protein, mouse; D012697:Serine Endopeptidases